Alumis (ALMS) Projected to Post Quarterly Earnings on Tuesday

Alumis (NASDAQ:ALMS) is anticipated to announce its Q2 2025 earnings results before the market opens on Tuesday, August 12th. Analysts expect the company to announce earnings of ($1.11) per share and revenue of $1.80 million for the quarter.

Alumis (NASDAQ:ALMS) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($1.82) earnings per share for the quarter, missing the consensus estimate of ($1.47) by ($0.35). On average, analysts expect Alumis to post $-9 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Alumis Stock Down 0.7%

ALMS stock opened at $4.30 on Friday. The business has a 50-day moving average of $3.48 and a 200-day moving average of $4.74. Alumis has a fifty-two week low of $2.76 and a fifty-two week high of $13.11.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC boosted its stake in shares of Alumis by 163.2% during the 2nd quarter. Geode Capital Management LLC now owns 1,167,832 shares of the company’s stock worth $3,504,000 after acquiring an additional 724,133 shares during the period. Goldman Sachs Group Inc. boosted its stake in shares of Alumis by 24.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 61,645 shares of the company’s stock worth $378,000 after acquiring an additional 11,949 shares during the period. Jane Street Group LLC bought a new position in shares of Alumis during the 1st quarter worth approximately $111,000. Rhumbline Advisers boosted its stake in shares of Alumis by 21.7% during the 1st quarter. Rhumbline Advisers now owns 16,543 shares of the company’s stock worth $102,000 after acquiring an additional 2,949 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Alumis by 64.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,535 shares of the company’s stock worth $77,000 after acquiring an additional 4,926 shares during the period.

Analyst Ratings Changes

ALMS has been the subject of several recent research reports. Wells Fargo & Company initiated coverage on Alumis in a research report on Friday, July 25th. They set an “overweight” rating and a $17.00 price objective for the company. Oppenheimer reduced their price objective on Alumis from $26.00 to $25.00 and set an “outperform” rating for the company in a research report on Thursday, May 15th. HC Wainwright reissued a “buy” rating and set a $14.00 price target on shares of Alumis in a research report on Friday, July 25th. Finally, Guggenheim raised Alumis to a “buy” rating and set a $18.00 price target for the company in a research report on Tuesday, June 10th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $19.80.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.